JP2005539000A - Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 - Google Patents

Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 Download PDF

Info

Publication number
JP2005539000A
JP2005539000A JP2004525405A JP2004525405A JP2005539000A JP 2005539000 A JP2005539000 A JP 2005539000A JP 2004525405 A JP2004525405 A JP 2004525405A JP 2004525405 A JP2004525405 A JP 2004525405A JP 2005539000 A JP2005539000 A JP 2005539000A
Authority
JP
Japan
Prior art keywords
mmol
pyridin
alkyl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004525405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005539000A5 (enExample
Inventor
ネリナ・ドディック
フランソワーズ・ジャンヌ・ジェリベール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217751A external-priority patent/GB0217751D0/en
Priority claimed from GB0314698A external-priority patent/GB0314698D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2005539000A publication Critical patent/JP2005539000A/ja
Publication of JP2005539000A5 publication Critical patent/JP2005539000A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004525405A 2002-07-31 2003-07-29 Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 Pending JP2005539000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217751A GB0217751D0 (en) 2002-07-31 2002-07-31 Compounds
GB0314698A GB0314698D0 (en) 2003-06-24 2003-06-24 Compounds
PCT/EP2003/008496 WO2004013135A1 (en) 2002-07-31 2003-07-29 2-phenylpyridin-4-yl derivatives as alk5 inhibitors

Publications (2)

Publication Number Publication Date
JP2005539000A true JP2005539000A (ja) 2005-12-22
JP2005539000A5 JP2005539000A5 (enExample) 2006-09-14

Family

ID=31497253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004525405A Pending JP2005539000A (ja) 2002-07-31 2003-07-29 Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体

Country Status (7)

Country Link
US (1) US20050245520A1 (enExample)
EP (1) EP1539748A1 (enExample)
JP (1) JP2005539000A (enExample)
AR (1) AR040726A1 (enExample)
AU (1) AU2003260345A1 (enExample)
TW (1) TW200417547A (enExample)
WO (1) WO2004013135A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537291A (ja) * 2002-07-31 2005-12-08 スミスクライン・ビーチャム・コーポレイション イミダゾ[1,2−a]ピリジン
JP2006502164A (ja) * 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド イミダゾロピリジンならびにその生成および使用方法
JP2006519249A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害薬としての新規縮合複素芳香族化合物
JP2009543765A (ja) * 2006-07-14 2009-12-10 ノバルティス アクチエンゲゼルシャフト Alk−5阻害剤としてのピリミジン誘導体
JP2011500623A (ja) * 2007-10-17 2011-01-06 ノバルティス アーゲー ALK阻害剤として有用なイミダゾ[1,2−a]ピリジン誘導体
JP2011509278A (ja) * 2008-01-11 2011-03-24 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2011074658A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
ES2325687T3 (es) 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
DE60330362D1 (de) 2002-09-18 2010-01-14 Pfizer Prod Inc Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
AP2005003262A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.
WO2004026863A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
HRP20050251A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tfg) inhibitors
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
WO2007002559A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
WO2007028051A2 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
US20100056505A1 (en) * 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
EP2121669A2 (en) * 2007-01-30 2009-11-25 Biogen Idec MA, Inc. Furanone compounds and methods of making and using the same
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
EA020847B1 (ru) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
UY33476A (es) * 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
CN102971293A (zh) * 2010-07-05 2013-03-13 默克专利有限公司 用于治疗激酶诱导的疾病的联吡啶衍生物
US8871744B2 (en) * 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP3112363A1 (en) * 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
SG11201500883YA (en) * 2012-08-07 2015-04-29 Aurigene Discovery Tech Ltd 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
DK3702443T3 (da) 2013-03-14 2022-04-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102493376B1 (ko) 2014-09-03 2023-01-27 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2018019106A1 (zh) 2016-07-29 2018-02-01 上海璎黎药业有限公司 含氮芳香杂环化合物、其制备方法、药物组合物和应用
JP2020500177A (ja) * 2016-11-14 2020-01-09 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. 3,4−ビピリジルピラゾール誘導体、およびその製造方法およびその医療応用
SG10201910821XA (en) 2016-12-30 2020-01-30 Frequency Therapeutics Inc 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN112601522B (zh) * 2018-07-09 2024-11-05 辛瑟斯治疗股份有限公司 抗体-alk5抑制剂偶联物及其用途
EP3837352A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2022515652A (ja) 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
CA3170142A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
WO2024032598A1 (zh) * 2022-08-08 2024-02-15 河南迈英诺医药科技有限公司 TGF-β抑制剂化合物及其用途
CN115490687B (zh) * 2022-09-19 2023-10-27 国家烟草质量监督检验中心 3-苯并呋喃基硫咪唑并吡啶衍生物及其制备方法和应用
WO2024155715A1 (en) * 2023-01-17 2024-07-25 Baylor College Of Medicine Inhibitors of activin receptor type 1 (acvr1) and activin receptor like type 1 (acvrl1), and methods using same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072737A1 (en) * 2000-03-27 2001-10-04 Smithkline Beecham Corporation Triarylimidazole derivatives as cytokine inhibitors
WO2002016359A1 (en) * 2000-08-22 2002-02-28 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
JP2002514599A (ja) * 1998-05-09 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリジニルイミダゾールによるプロテインキナーゼの阻害
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
WO2002040476A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Pyridyl-substituted triazoles as tgf inhibitors
JP2005537291A (ja) * 2002-07-31 2005-12-08 スミスクライン・ビーチャム・コーポレイション イミダゾ[1,2−a]ピリジン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514599A (ja) * 1998-05-09 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ピリジニルイミダゾールによるプロテインキナーゼの阻害
WO2001072737A1 (en) * 2000-03-27 2001-10-04 Smithkline Beecham Corporation Triarylimidazole derivatives as cytokine inhibitors
WO2002016359A1 (en) * 2000-08-22 2002-02-28 Glaxo Group Limited Fused pyrazole derivatives being protein kinase inhibitors
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
WO2002040476A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Pyridyl-substituted triazoles as tgf inhibitors
JP2005537291A (ja) * 2002-07-31 2005-12-08 スミスクライン・ビーチャム・コーポレイション イミダゾ[1,2−a]ピリジン

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537291A (ja) * 2002-07-31 2005-12-08 スミスクライン・ビーチャム・コーポレイション イミダゾ[1,2−a]ピリジン
JP2006502164A (ja) * 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド イミダゾロピリジンならびにその生成および使用方法
JP2006519249A (ja) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害薬としての新規縮合複素芳香族化合物
JP2009543765A (ja) * 2006-07-14 2009-12-10 ノバルティス アクチエンゲゼルシャフト Alk−5阻害剤としてのピリミジン誘導体
JP2011500623A (ja) * 2007-10-17 2011-01-06 ノバルティス アーゲー ALK阻害剤として有用なイミダゾ[1,2−a]ピリジン誘導体
JP2011509278A (ja) * 2008-01-11 2011-03-24 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2011074658A1 (ja) * 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
JPWO2011074658A1 (ja) * 2009-12-18 2013-05-02 田辺三菱製薬株式会社 新規抗血小板薬
US8703760B2 (en) 2009-12-18 2014-04-22 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent
AU2010331175B2 (en) * 2009-12-18 2014-08-28 Mitsubishi Tanabe Pharma Corporation Novel antiplatelet agent
US9533983B2 (en) 2009-12-18 2017-01-03 Mitsubishi Tanabe Pharma Corporation Antiplatelet agent

Also Published As

Publication number Publication date
AU2003260345A1 (en) 2004-02-23
US20050245520A1 (en) 2005-11-03
AR040726A1 (es) 2005-04-20
TW200417547A (en) 2004-09-16
EP1539748A1 (en) 2005-06-15
WO2004013135A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
JP2005539000A (ja) Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体
US20060058329A1 (en) Pyrazole inhibitors of the transforming growth factor
EP1268465B1 (en) Triarylimidazole derivatives as cytokine inhibitors
US6465493B1 (en) Triarylimidazoles
EP1543003B1 (en) Imidazo¬1,2-a|pyridines
US20050165011A1 (en) Benzoxazine and benzoxazinone substituted triazoles
CZ283070B6 (cs) Fenoxy- a fenoxyalkylpiperidiny jako protivirově účinné látky
WO2013100672A1 (ko) 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체
JP2020516672A (ja) 治療用化合物
JP5828188B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP2006527722A (ja) Alk−5受容体の阻害剤としての4−(ヘテロサイクル−縮合フェニル)−3−(フェニルまたはピリド−2−イル)ピラゾール
JP2005538997A (ja) Tgf−ベータシグナル伝達経路の阻害剤としてのピリジニル置換(1,2,3)トリアゾール
JP2006527720A (ja) Alk−5受容体の阻害剤としてのチアゾール
JP2005538996A (ja) 化合物
TW202237088A (zh) 作為抗癌劑的三環化合物
CN113164444A (zh) Dock1抑制化合物及其用途
HK1181655A1 (zh) 杂芳基甲酰胺

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608